A New Standard for Copay Excellence: How Pharma Can Rethink Affordability

As out‑of‑pocket costs rise and insurance designs grow more complex, traditional copay models are being pushed to their limits. High‑deductible plans, accumulator and maximizer programs, and growing payer and PBM variability are fundamentally reshaping how manufacturer affordability programs operate. 

In a recent Q&A with Pharmaceutical Executive, Brian Laird, President, Patient Services, shares his perspective on how the copay marketplace has evolved and why a more intelligent, data‑driven approach is redefining what “good” looks like in copay support. 

Read the full Q&A with Brian Laird in Pharmaceutical Executive 

Why Copay Programs Are No Longer Simple 

Copay programs once operated as relatively straightforward reimbursement mechanisms. Today, they function as strategic levers that directly influence patient access and manufacturer financial performance. Expectations have shifted. Manufacturers demand greater transparency, stronger controls, and clearer insight into how affordability dollars are spent and protected. 

The Largest Barriers to Effective Copay Support 

One of the most persistent challenges is the perceived tradeoff between expanding access and controlling cost. Broader assistance can expose programs to rapid spend, fraud, and limited visibility. Infrastructure also plays a critical role. Many legacy copay systems rely on static, single‑pathway adjudication models that were not designed for today’s complexity, increasing risk when outages, policy changes, or payer tactics disrupt access. 

Why we Rethought the Model 

With experience managing 80+ active copay programs, processing 12 million claims annually, and supporting 1.5 million patients, our team saw a clear gap between manufacturer needs and traditional solutions. Too many programs were still treated as transactional services rather than strategic financial tools. 

EVERSANA’s Intelligent Copay Solution was built to shift from a one‑size‑fits‑all approach to a more dynamic marketplace model, offering manufacturers better control over spend, stronger protection against risk, and confidence that patient access will remain intact as the market evolves. 

What’s Next for Copay Programs 

Looking ahead, successful copay programs will be more adaptive, transparent, and patient‑centric. Static rules and manual oversight will no longer suffice. Patients don’t think in terms of program mechanics; they think in terms of affordability, access, and staying on therapy. Programs that remove friction while remaining financially sustainable will define the new standard. 

Learn more about EVERSANA’s approach to copay and affordability programs